Teva Pharmaceutical Industries (NYSE:TEVA) earnings and shareholder returns have been trending downwards for the last five years, but the stock lifts 3.6% this past week
Teva Pharma Q2 Revenues Drop 18% | BioSpace
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire